{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:19:27Z","timestamp":1772691567622,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF18OC0052974"],"award-info":[{"award-number":["NNF18OC0052974"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["tipsro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Technical Innovations & Patient Support in Radiation Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.tipsro.2025.100368","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:35:36Z","timestamp":1765413336000},"page":"100368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimising acute toxicity monitoring in prostate MR-guided radiotherapy workflow: Results from a prospective study using multiple electronic PRO assessments"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0761-8028","authenticated-orcid":false,"given":"Pia Krause","family":"M\u00f8ller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-5372","authenticated-orcid":false,"given":"Helle","family":"Pappot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tine","family":"Schytte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-2696","authenticated-orcid":false,"given":"Uffe","family":"Bernchou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4766-3242","authenticated-orcid":false,"given":"Karin Brochstedt","family":"Dieperink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tipsro.2025.100368_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112916","article-title":"Clinical applications of magnetic Resonance-Guided Radiotherapy: a Narrative Review","volume":"15","author":"Ladbury","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tipsro.2025.100368_b0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clon.2022.03.002","article-title":"When less is more: the rising Tide of Hypofractionation","volume":"34","author":"Aitken","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.tipsro.2025.100368_b0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(24)00720-4","article-title":"The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials","volume":"26","author":"Nikitas","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0020","first-page":"281","article-title":"Patient adherence to patient-reported outcome measure (PROM) completion in clinical care: current understanding and future recommendations","volume":"33","author":"Unni","year":"2024","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehab"},{"key":"10.1016\/j.tipsro.2025.100368_b0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03906-1","article-title":"Patient-reported outcome measures add value as clinical trial endpoints","author":"Crossnohere","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.tipsro.2025.100368_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.652889","article-title":"Sensible Introduction of MR-Guided Radiotherapy: a Warm Plea for the RCT","volume":"11","author":"Verkooijen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0035","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210800","article-title":"MR-guided radiotherapy for prostate cancer: state of the art and future perspectives","volume":"95","author":"Sritharan","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.tipsro.2025.100368_b0040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic Body Radiation Therapy for Localized Prostate Cancer: a Systematic Review and Meta-Analysis of over 6,000 patients Treated on prospective Studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.tipsro.2025.100368_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.616291","article-title":"MR-Guided Radiotherapy for Prostate Cancer","volume":"10","author":"Tocco","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0050","unstructured":"National Institutes of Health NCI. Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. 2019."},{"key":"10.1016\/j.tipsro.2025.100368_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.05.028","article-title":"Patient reported outcomes following MR-guided radiotherapy for prostate cancer: a systematic review and meta-analysis","author":"Westerhoff","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.tipsro.2025.100368_b0060","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.3390\/cancers13194866","article-title":"1.5T magnetic Resonance-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer: Preliminary Clinical results of Clinician- and Patient-Reported Outcomes","volume":"13","author":"Poon","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tipsro.2025.100368_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10153396","article-title":"Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: less Time, Equal results","volume":"10","author":"Sandoval","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.tipsro.2025.100368_b0070","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-022-04092-2","article-title":"Van Der Voort Van Zyp JRN. the first patient-reported outcomes from the Utrecht Prostate Cohort (UPC): the first platform facilitating \u2018trials within cohorts\u2019 (TwiCs) for the evaluation of interventions for prostate cancer","author":"Teunissen","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.tipsro.2025.100368_b0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic Resonance Imaging\u2013Guided vs Computed Tomography\u2013Guided Stereotactic Body Radiotherapy for Prostate Cancer","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0080","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.radonc.2022.04.022","article-title":"Accumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy","volume":"171","author":"Willigenburg","year":"2022","journal-title":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"10.1016\/j.tipsro.2025.100368_b0085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijrobp.2022.08.041","article-title":"Quality-of-Life Outcomes and Toxicity Profile among patients with Localized Prostate Cancer after Radical Prostatectomy Treated with Stereotactic Body Radiation: the SCIMITAR Multicenter phase 2 Trial","volume":"115","author":"Ma","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.tipsro.2025.100368_b0090","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2020.05.007","article-title":"Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: final results on Patient-reported Outcomes of a prospective phase 2 Study","volume":"4","author":"Tetar","year":"2021","journal-title":"European urology oncology"},{"key":"10.1016\/j.tipsro.2025.100368_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12121982","article-title":"1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the first 100 patients","volume":"12","author":"Alongi","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.tipsro.2025.100368_b0100","article-title":"Magnetic Resonance\u2013Guided Prostate Stereotactic Body Radiation Therapy with Daily Online Plan Adaptation: results of a prospective phase 1 Trial and Supplemental Cohort","volume":"7","author":"Leeman","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0105","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.3390\/jcm11164651","article-title":"First Experience and prospective Evaluation on Feasibility and Acute Toxicity of Online Adaptive Radiotherapy of the Prostate Bed as Salvage Treatment in patients with Biochemically Recurrent Prostate Cancer on a 1.5T MR-Linac","volume":"11","author":"Wegener","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.tipsro.2025.100368_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081943","article-title":"Magnetic Resonance-Guided Reirradiation for Local Recurrence within the Prostate or in the Prostate Bed: One-Year Clinical results of a prospective Registry Study","volume":"14","author":"Michalet","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tipsro.2025.100368_b0115","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.prro.2022.09.007","article-title":"Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: the first results from the MOMENTUM study-an International Registry for the Evidence-based Introduction of magnetic Resonance-Guided Adaptive Radiation Therapy","volume":"13","author":"Teunissen","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0120","article-title":"Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial","volume":"46","author":"Fink","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0125","article-title":"Stereotactic magnetic Resonance-Guided Daily Adaptive Radiation Therapy for Localized Prostate Cancer: Acute and late Patient-Reported Toxicity Outcomes","volume":"9","author":"Nugent","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.tipsro.2025.100368_b0135","article-title":"MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study. Clinical and Translational","author":"Sritharan","year":"2024","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0140","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/17407745221093935","article-title":"Timing is everything: the importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events","volume":"19","author":"King-Kallimanis","year":"2022","journal-title":"Clin Trials"},{"key":"10.1016\/j.tipsro.2025.100368_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctro.2023.100612","article-title":"Acute and late toxicity patterns of moderate hypo-fractionated radiotherapy for prostate cancer: a systematic review and meta-analysis","volume":"40","author":"Sinzabakira","year":"2023","journal-title":"Clinical and Translational Radiation Oncology"},{"key":"10.1016\/j.tipsro.2025.100368_b0150","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1016\/S2352-3026(20)30067-3","article-title":"Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial","volume":"7","author":"Thanarajasingam","year":"2020","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.tipsro.2025.100368_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.01.010","article-title":"Personalised radiation therapy taking both the tumour and patient into consideration","author":"Overgaard","year":"2022","journal-title":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"10.1016\/j.tipsro.2025.100368_b0160","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0360-3016(98)00475-1","article-title":"Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy","volume":"43","author":"Lilleby","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.tipsro.2025.100368_b0165","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2013.05.038","article-title":"Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up","volume":"108","author":"Ferrer","year":"2013","journal-title":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"},{"key":"10.1016\/j.tipsro.2025.100368_b0170","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2015.01.008","article-title":"Impact of age on quality-of-life outcomes after treatment for localized prostate cancer","volume":"68","author":"Hampson","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.tipsro.2025.100368_b0175","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.eururo.2017.06.035","article-title":"Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: a Systematic Review","volume":"72","author":"Lardas","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.tipsro.2025.100368_b0180","doi-asserted-by":"crossref","DOI":"10.1111\/bju.15739","article-title":"Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study)","author":"Lane","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.tipsro.2025.100368_b0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctro.2019.03.006","article-title":"Prostate cancer \u2013 Advantages and disadvantages of MR-guided RT","volume":"18","author":"Murray","year":"2019","journal-title":"Clinical and Translational Radiation Oncology"},{"key":"10.1016\/j.tipsro.2025.100368_b0190","first-page":"9","article-title":"The MOMENTUM Study: an International Registry for the Evidence-based Introduction of MR-Guided Adaptive Therapy","volume":"10","author":"van Otterloo","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s41687-021-00326-w","article-title":"Development of patient-reported outcomes item set to evaluate acute treatment toxicity to pelvic online magnetic resonance-guided radiotherapy","volume":"5","author":"M\u00f8ller","year":"2021","journal-title":"Journal of Patient-Reported Outcomes"},{"key":"10.1016\/j.tipsro.2025.100368_b0200","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tipsro.2021.12.001","article-title":"Feasibility, usability and acceptance of weekly electronic patient-reported outcomes among patients receiving pelvic CT- or online MR-guided radiotherapy \u2013 a prospective pilot study","volume":"21","author":"M\u00f8ller","year":"2022","journal-title":"Technical Innovations & Patient Support in Radiation Oncology"},{"issue":"35","key":"10.1016\/j.tipsro.2025.100368_b0205","first-page":"939","article-title":"Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. European journal of cancer (Oxford","volume":"1999","author":"Fitzsimmons","year":"1990","journal-title":"England"},{"key":"10.1016\/j.tipsro.2025.100368_b0210","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.tipsro.2025.100368_b0215","author":"My","year":"2021","journal-title":"Hospital Centre for Innovative Medical Technology"},{"key":"10.1016\/j.tipsro.2025.100368_b0220","unstructured":"Foundation ER. EQ-5D-5L User Guide. Basic information on how to use the EQ-5D-5L instrument. 3.0 ed2021."},{"key":"10.1016\/j.tipsro.2025.100368_b0225","unstructured":"EORTC. EORTC QLQ-C30 Scoring Manual, third edition. 2001."},{"key":"10.1016\/j.tipsro.2025.100368_b0230","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"48","key":"10.1016\/j.tipsro.2025.100368_b0235","first-page":"1713","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. European journal of cancer (Oxford","volume":"2012","author":"Cocks","year":"1990","journal-title":"England"},{"key":"10.1016\/j.tipsro.2025.100368_b0240","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0245","series-title":"R: a Language and Environment for Statistical Computing","author":"Team RC","year":"2023"},{"key":"10.1016\/j.tipsro.2025.100368_b0250","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial","volume":"13","author":"Dearnaley","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0255","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tipsro.2025.100368_b0260","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijrobp.2015.02.021","article-title":"Systematic Review of Radiation Therapy Toxicity Reporting in Randomized Controlled Trials of Rectal Cancer: a Comparison of Patient-Reported Outcomes and Clinician Toxicity Reporting","volume":"92","author":"Gilbert","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.tipsro.2025.100368_b0265","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2021.08.034","article-title":"FACE Value of Patient-Reported Outcomes in Dose-Escalated Radiation Therapy for Prostate Cancer","volume":"112","author":"Glicksman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Technical Innovations & Patient Support in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405632425000691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405632425000691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T04:27:53Z","timestamp":1772684873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405632425000691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"alternative-id":["S2405632425000691"],"URL":"https:\/\/doi.org\/10.1016\/j.tipsro.2025.100368","relation":{},"ISSN":["2405-6324"],"issn-type":[{"value":"2405-6324","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimising acute toxicity monitoring in prostate MR-guided radiotherapy workflow: Results from a prospective study using multiple electronic PRO assessments","name":"articletitle","label":"Article Title"},{"value":"Technical Innovations & Patient Support in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tipsro.2025.100368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy & Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100368"}}